Clinical trials: Clinically Isolated Syndrome, CNS Demyelinating
Clinically Isolated Syndrome (CIS), Multiple Sclerosis (MS)
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
This a retrospective, blinded trial in which collaborators in Italy will review the doppler findings from the Combined Transcranial and Extracranial Venous Doppler (CTEVD) trial in an attempt to measure reproducibility.
- Conditions
- Clinically Isolated Syndrome (CIS), Multiple Sclerosis (MS), Other Neurological Disorders (OND), Healthy (HC)
- Trial name
- NCT02308579
- Volunteers
- 499 people
- Sponsor
- University at Buffalo
Relapsing Remitting Multiple Sclerosis, Clinically Isolated Syndrome
Clinical Importance of Glucose Regulation in Relapsing MS
The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery…
- Trial name
- NCT03004079
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Virginia
Multiple Sclerosis, Relapsing-Remitting
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.
- Trial name
- RIFUND-MS (NCT02746744)
- Testing
- Rituximab, Dimethyl fumarate, Sodium Chloride solution
- Where
- 17 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Anders Svenningsson
Multiple Sclerosis
Sociocognitive Intervention and Rehabilitation Program in Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system, involving inflammation, demyelination, and neurodegeneration. It is the most common non-traumatic disabling disease affecting young adults.
- Trial name
- REACT-MS (NCT07734675)
- Testing
- Sociocognitive rehabilitation via COGWEB platform combined with an emotional processing intervention.
- Where
- 2 sites in Portugal
- Volunteers
- 130 people
- Sponsor
- Sonia Batista
Multiple Sclerosis
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive…
- Trial name
- ADHERENCE (NCT03408093)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Volunteers
- 120 people
- Sponsor
- Bayer
Multiple Sclerosis, Clinically Isolated Syndrome
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
This project aims to analyze ocular motility problems, visual processing speed and microperimetry, and their relationship with consolidated retinal structural biomarkers (optical coherence tomography, OCT) in patients with…
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
- Trial name
- NCT05706220
- Testing
- Eye tracking, Microperimetry, Optical coherence tomography (OCT)
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Multiple Sclerosis, Clinically Isolated Syndrome
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
This study will evaluate the potential placental transfer of ocrelizumab in pregnant women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of…
- Trial name
- MINORE (NCT04998812)
- Testing
- Ocrelizumab
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
The purpose of this study is to obtain long-term clinical data from patients approximately 15 years after their first clinical event, who participated in the former BENEFIT 304747 study and were treated at least once within that…
- Trial name
- NCT03269175
- Testing
- Brain MRI, Blood sampling
- Where
- 61 sites in Austria, Belgium and 16 more
- Volunteers
- 261 people
- Sponsor
- Bayer
Clinically Isolated Syndrome, Multiple Sclerosis
Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion
This is a multicentric and prospective study for the validation of a diagnostic method in multiple sclerosis. Our hypothesis is that there is a characteristic profile of tears that can be recognized in order to help in the…
- Trial name
- POLAR (NCT02043964)
- Testing
- tears and cerebrospinal fluid sampling
- Where
- 15 sites in France
- Volunteers
- 165 people
- Sponsor
- Lille Catholic University
Multiple Sclerosis
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
- Trial name
- ENCORE (NCT01167426)
- Testing
- Glatiramer Acetate 20 mg/0.5 mL
- Volunteers
- 148 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis (MS), Relapsing-Remitting MS
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
This study intends to explore evolution of MSRV expression by analyzing the levels of MSRV transcripts in blood, as well as the levels of the MSRV-Env protein in serum of MS patients.
- Conditions
- Multiple Sclerosis (MS), Relapsing-Remitting MS, Primary Progressive MS, Secondary Progressive MS
- Trial name
- LOMBARD (NCT01804647)
- Testing
- No study treatments administered - blood draws only
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 58 people
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis, Clinically Isolated Syndrome
Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI
Using an automatic software tool, Pixyl.Neuro, to conduct a retrospective analysis (detection of lesions + segmentation of images + tracking over time) of cerebral MRI images acquired during a prospective study of patients…
- Trial name
- PIXCIS (NCT03438357)
- Testing
- Analysis of cerebral MRI with automatic segmentation software
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Clinically Isolated Syndrome
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
The Multiple Sclerosis Functional Composite (MSFC), a reliable and well-validated instrument, was developed as a multidimensional quantitative measure of neurologic disability in MS.
- Trial name
- MSPT (NCT04599023)
- Testing
- MSPT
- Where
- Switzerland
- Volunteers
- 182 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Relapsing Forms of MS
Study of Diroximel Fumarate in the Real-World Setting
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- NCT04746976
- Testing
- Diroximel Fumarate
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Biogen
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)
The goal of this observational study is to learn about the role of kappa free light chains (KFLC) in cerebrospinal fluid (CSF) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndrome (CIS).
- Trial name
- PRO-KFLC (NCT07183020)
- Testing
- Oligoclonal bands and kappa free light chains (KFLC)
- Where
- Germany
- Volunteers
- 1,142 people
- Sponsor
- Skripuletz, Thomas Prof. Dr.
Relapsing Remitting Multiple Sclerosis
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
To determine the safety and tolerability of BOSWELAN in subjects with multiple sclerosis or clinically isolated syndrome and to describe the effect of Boswellic acids on the disease activity as assessed by monthly MRI measures.
- Trial name
- SABA (NCT01450124)
- Testing
- Boswellic acids (BOSWELAN)
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Clinically Isolated Syndrome, Multiple Sclerosis
Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome
Optic neuritis (ON) represents around 30% of clinical presentation of clinically isolated syndrome (CIS). Asymptomatic optic nerve involvement is very frequent in all stage of multiple sclerosis (MS) disease including the CIS.
- Trial name
- HdeFIMS (NCT06455332)
- Testing
- Optic nerve MRI sequence
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Lille
Multiple Sclerosis, Clinically Isolated Syndrome
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
The definition of the most 'at-risk' population within highly susceptible groups would provide an opportunity for preemptive therapeutics.
- Trial name
- ARMS (NCT00617383)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis, Clinically Isolated Syndrome
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with…
- Trial name
- SOPRANINO (NCT04998851)
- Testing
- Ocrelizumab
- Where
- 8 sites in United States, Spain and 1 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients
This is a longitudinal single blind randomized trial to test the effects of high compared to low dose vitamin D3 supplementation on cognitive performance at 6 and 12 months, and MRI measures of 12 months duration.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome, Clinically Isolated Syndrome, CNS Demyelinating
- Trial name
- NCT03610139
- Testing
- Vitamin D3
- Where
- Lebanon
- Volunteers
- 162 people
- Sponsor
- American University of Beirut Medical Center